Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · IEX Real-Time Price · USD
12.82
-1.02 (-7.37%)
May 16, 2024, 4:00 PM EDT - Market closed
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
344.38M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 2 days ago - Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 7 days ago - Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences - Business Wire
- 23 days ago - Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia - Business Wire
- 6 weeks ago - Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder - Business Wire
- 2 months ago - Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors - Business Wire
- 2 months ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference - Business Wire